UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

European journal of cancer (1990), 2014-01, Vol.50 (1), p.78-84

2014

Volltextzugriff (PDF)

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

European journal of cancer (1990), 2012-01, Vol.48 (1), p.85-93

2012

Volltextzugriff (PDF)

Molecular alterations and emerging targets in castration resistant prostate cancer

European journal of cancer (1990), 2014-03, Vol.50 (4), p.753-764

2014

Volltextzugriff (PDF)

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

Lung cancer (Amsterdam, Netherlands), 2014-08, Vol.85 (2), p.141-146

2014

Volltextzugriff (PDF)

Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer

Clinical radiology, 2015-04, Vol.70 (4), p.359-365

2015

Volltextzugriff (PDF)

Prostate Radiotherapy for Men with Metastatic Disease: A New Comparison in the STAMPEDE Trial

Clinical oncology (Royal College of Radiologists (Great Britain)), 2013-05, Vol.25 (5), p.318-320

2013

Volltextzugriff (PDF)

Targeting insulin and insulin-like growth factor signalling in oncology

Current opinion in pharmacology, 2008-08, Vol.8 (4), p.384-392

2008

Volltextzugriff (PDF)

Therapeutic strategies for inhibiting oncogenic BRAF signaling

Current opinion in pharmacology, 2008-08, Vol.8 (4), p.419-426

2008

Volltextzugriff (PDF)

Emerging cancer therapeutic opportunities by inhibiting mitotic kinases

Current opinion in pharmacology, 2008-08, Vol.8 (4), p.375-383

2008

Volltextzugriff (PDF)

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

The lancet oncology, 2019-03, Vol.20 (3), p.383-393

2019

Volltextzugriff (PDF)

Granulocyte macrophage colony-stimulating factor and interleukin-3 regulate chemokine and chemokine receptor expression in bone marrow macrophages

Experimental hematology, 1999-12, Vol.27 (12), p.1735-1745

1999

Volltextzugriff (PDF)

The ErbB receptor family: a therapeutic target for cancer

Trends in Molecular Medicine, 2002-01, Vol.8 (4), p.S19-S26

2002

Volltextzugriff (PDF)

PCN315 - Physicians’ Behavior Influences the Health and Economic Impact of Applying Circulating Tumor Cells as Response Marker in Metastatic Castration-Resistant Prostate Cancer

Value in health, 2016-11, Vol.19 (7), p.A765-A766

2016

Volltextzugriff (PDF)

Physicians’ Behavior Influences the Health and Economic Impact of Applying Circulating Tumor Cells as Response Marker in Metastatic Castration-Resistant Prostate Cancer

Value in health, 2016-11, Vol.19 (7), p.A765-A766

2016

Volltextzugriff (PDF)

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma

Seminars in oncology, 2003-10, Vol.30 (5), p.79-92

2003

Volltextzugriff (PDF)

Visceral Disease in Castration-resistant Prostate Cancer

European urology, 2014-02, Vol.65 (2), p.270-273

2014

Volltextzugriff (PDF)

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The lancet oncology, 2015-02, Vol.16 (2), p.152-160

2015

Volltextzugriff (PDF)

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

European urology, 2019-01, Vol.75 (1), p.88-99

2019

Volltextzugriff (PDF)

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

Cell, 2018-06, Vol.173 (7), p.1770-1782.e14

2018

Volltextzugriff (PDF)

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting

European urology, 2018-05, Vol.73 (5), p.715-723

2018

Volltextzugriff (PDF)

Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer

European urology, 2019-12, Vol.76 (6), p.843-851

2019

Volltextzugriff (PDF)

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

The lancet oncology, 2009-03, Vol.10 (3), p.233-239

2009

Volltextzugriff (PDF)

Payoff- and Sex-Biased Social Learning Interact in a Wild Primate Population

Current biology, 2018-09, Vol.28 (17), p.2800-2805.e4

2018

Volltextzugriff (PDF)

Machine learning versus logistic regression for the prediction of complications after pancreatoduodenectomy

Surgery, 2023-09, Vol.174 (3), p.435-440

2023

Volltextzugriff (PDF)

1 – 25 von 352

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(310)
Mit Volltextzugriff
(332)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(156)
Life Sciences & Biomedicine
(147)
Humans
(132)
Male
(98)
Hematology, Oncology And Palliative Medicine
(59)
Middle Aged
(59)
Biological And Medical Sciences
(55)
Aged
(53)
Female
(50)
Medical Sciences
(49)
Oncology
(36)
Adult
(35)
Urology & Nephrology
(35)
Treatment Outcome
(29)
Urology
(28)
Prostate Cancer
(24)
Prostatic Neoplasms, Castration-Resistant - Drug Therapy
(24)
Pharmacology. Drug Treatments
(22)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(20)
Tumors
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

Molecular alterations and emerging targets in castration resistant prostate cancer

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer

Prostate Radiotherapy for Men with Metastatic Disease: A New Comparison in the STAMPEDE Trial

Targeting insulin and insulin-like growth factor signalling in oncology

Therapeutic strategies for inhibiting oncogenic BRAF signaling

Emerging cancer therapeutic opportunities by inhibiting mitotic kinases

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Granulocyte macrophage colony-stimulating factor and interleukin-3 regulate chemokine and chemokine receptor expression in bone marrow macrophages

The ErbB receptor family: a therapeutic target for cancer

PCN315 - Physicians’ Behavior Influences the Health and Economic Impact of Applying Circulating Tumor Cells as Response Marker in Metastatic Castration-Resistant Prostate Cancer

Physicians’ Behavior Influences the Health and Economic Impact of Applying Circulating Tumor Cells as Response Marker in Metastatic Castration-Resistant Prostate Cancer

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma

Visceral Disease in Castration-resistant Prostate Cancer

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting

Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

Payoff- and Sex-Biased Social Learning Interact in a Wild Primate Population

Machine learning versus logistic regression for the prediction of complications after pancreatoduodenectomy

Aktive Filter

Suchergebnisse filtern